Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the USA. To evaluate the clinical impact of bevacizumab as a first-line drug for glioblastoma, two randomized clinical trials,...
Spremljeno u:
| Glavni autori: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2020-12-01
|
| Serija: | Pharmaceuticals |
| Teme: | |
| Online pristup: | https://www.mdpi.com/1424-8247/13/12/470 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|